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CIS = common insertion site; IM = insertional mutagenesis; MMTV = mouse mammary tumour virus; MoMuLV = Moloney murine leukaemia virus;
PB = PiggyBac transposon; PCR = polymerase chain reaction; PDGF = platelet-derived growth factor; SB = Sleeping Beauty transposon.
Available online http://breast-cancer-research.com/content/8/1/102
Abstract
Knowledge of the genes and genetic pathways involved in onco-
genesis is essential if we are to identify novel targets for cancer
therapy. Insertional mutagenesis in mouse models is among the
most efficient tools to detect novel cancer genes. Retrovirus-
mediated insertional mutagenesis received a tremendous boost by
the availability of the mouse genome sequence and new PCR
methods. Application of such advances were limited to lympho-
magenesis but are now also being applied to mammary
tumourigenesis. Novel transposons that allow insertional muta-
genesis studies to be conducted in tumors of any mouse tissue
may give cancer gene discovery a further boost.
Introduction
Oncogenic transformation of a normal cell is a multistep
process that requires activation or inactivation, usually by
mutagenic events, of several key genes controlling various
essential cellular pathways that are involved in growth and
development. An understanding of which pathways and genes
are involved is essential to the development of novel therapeutic
strategies. Although a large number of genes involved in breast
and other cancers has been discovered, the picture is far from
complete. Retroviral insertional mutagenesis (IM) in mouse
models is among the most efficient tools to uncover cancer
genes. The most important advantage of IM over chemical and
radiation induced mutagenesis is that the mutagen is also a
molecular tag, facilitating the identification of the mutated locus.
Because proviral integration is essentially random with some
bias for transcriptionally active domains, retroviral insertions in
the same genomic locus in multiple independent tumours mark
a so-called common insertion site (CIS), which is likely to
contain a gene involved in tumourigenesis.
IM was first described in 1981 by Hayward and coworkers [1]
when those investigators, in an effort to elucidate the
mechanism by which avian leukosis virus induces lymphomas,
discovered that the virus targeted the cellular Myc gene. Shortly
thereafter, Nusse and Varmus [2] identified Wnt1 as a frequent
target of mouse mammary tumour virus (MMTV) using this
approach. IM mediated by retroviruses is based on the
integration of a DNA copy of retroviral RNA as a provirus into
the cellular genome as part of the life cycle of the virus. The
regulatory elements in the proviral long terminal repeats can
then transcriptionally activate adjacent cellular genes. Proviral
insertions that truncate cellular genes giving rise to
dysfunctional or constitutively active proteins are also frequently
found; for an extensive overview of retroviral IM, see the reports
by Jonkers and Berns [3] and Mikkers and Berns [4].
Although these landmark studies were followed by several
others, the number of oncogenes discovered in this way
remained rather limited. This was mainly due to the rather
laborious techniques, including Southern blotting, extensive
cloning of DNA fragments and ‘chromosome walking’,
needed to identify the affected gene. The availability of novel
PCR technologies such as the splinkerette [5] and inverse
PCR [6], but in particular the completion of the draft
sequence of the mouse genome, permitted high-throughput
screening strategies and caused a revival of the IM approach
to gene discovery. Hundreds of novel candidate oncogenes
involved in lymphomagenesis have recently been reported
using Moloney murine leukaemia virus (MoMuLV) [5,7-10].
Despite these technological advances, no large-scale
screening for CISs in other neoplasias was conducted until
very recently. Here I review some of the recent papers that
used new opportunities for gene discovery in brain and
mammary tumourigenesis [8,11,12]. In addition, I discuss
transposon-mediated IM in mice, which has now achieved a
degree of maturity and in theory allows high-throughput
cancer gene discovery studies in any tissue.
Insertional mutagenesis in mouse mammary
tumours
Thus far, no more than 12 genes with proven oncogenicity
have been found by MMTV tagging in mouse mammary
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tumours (Table 1). One of these (Int5) may only be involved in
hormone-dependent growth, whereas the oncogenic potential
of two genes (Int41 and the novel Int7 gene [12]) remains to
be established. Although not all of these genes are involved
in human breast cancer, most of the pathways in which they
act have been implicated in human disease. Remarkably, the
list of confirmed oncogenes is mainly composed of Wnt, Fgf
and Notch genes, which are involved in development of the
embryonic mammary gland. Int7 belongs to a novel class of
oncogenes [12]. Although its oncogenicity is yet to be
established, its discovery shows that MMTV-mediated IM still
has the potential to identify new classes of oncogenes in
mammary tumourigenesis. Also, the sky rocketing number of
candidate oncogenes found in the high-throughput MoMuLV
mediated IM studies in lymphomagenesis indicates that
MMTV-mediated gene tagging in mammary tumourigenesis
needs further exploration. An obvious question arising is
whether proviral MoMuLV and MMTV may tag the same
genes. Comparison of the loci tagged by MMTV in mammary
tumours identified in our own recent semi-high-throughput
study (Theodorou V, Boer M, Kimm M, Theelen W, Jonkers J,
Hilkens J, unpublished data) with the loci tagged by MoMuLV
in murine lymphomas deposited in the mouse Retrovirus
Tagged Cancer Gene Database [13] suggests that the
overlap is small. This indicates that the cancer-associated
signal transduction pathways in mammary tumourigenesis
and lymphomagenesis are at least partly different and
warrants further high-throughput IM studies.
New technological developments
Insertional mutagenesis with modified retroviruses
Collaborating oncogenes (i.e. genes that act together in
tumourigenesis) can also be identified by IM because they
are frequently coactivated in the same tumours. IM in
oncogene-expressing transgenic mice is frequently used to
identify oncogene collaboration more directly. This method
was used to show, for example, that Wnt and  Fgf genes
collaborate in mammary tumourigenesis [14]. Recently,
Johansson and coworkers [8] used another IM approach to
seek collaborating genes. Based on the notion that autocrine
stimulation of the PDGF receptors is a frequent event in
glioblastoma development, they administered to mice an
intracerebral injection of recombinant MoMuLV encoding
platelet-derived growth factor (PDGF)-β (together with a wild-
type MoMuLV helper virus). The recombinant virus not only
predisposed these mice to gliomas, but MoMuLV also
efficiently tagged oncogenes in the brain, potentially
collaborating with PDGF-β. This experiment also shows that
nonhaematopoietic cells can be predisposed in such a way
that these cells accumulate sufficient insertions to develop
into tumours before haematopoietic cells, which are the prime
targets of MoMuLV, can do so. However, local virus injection
may also have contributed to the absence of lymphomas in
these animals.
The authors identified 66 loci that harbour potential brain
tumour-associated oncogenes that collaborate with PDGF-β.
In a subsequent report [15], it was shown that most of the
common retroviral insertions indeed affected the predicted
genes – evidence that recent high-throughput studies often
lack. Some of these candidate oncogenes were previously
not known to be involved in (brain) tumourigenesis.
Transposon-mediated cancer gene tagging
Until recently, retrovirally induced IM was not applied in solid
tumours with the exception of mouse mammary tumours and
Table 1
Oncogenes and candidate oncogenes detected by MMTV insertional mutagenesis in mouse mammary tumours
Confirmed  Evidence for involvement 
Gene Gene product oncogenicity in human breast cancer Reference
Fgf3/int2 Fibroblast growth factor Yes No [22]
Fgf4 Fibroblast growth factor Yes No [23]
Fgf8 Fibroblast growth factor Yes Yes [24]
Fgf10 Fibroblast growth factor Yes Yes [11]
Int-5IInt-H Aromatase Yes Yes [25]
Int6/Eif3e Translation initiation factor 3 subunit Yes No [26]
Int7 Thrombospondin domain containing gene No No [12]
Int-41 Unknown No No [27]
Map3k8/Tpl2 Mitogen-activated protein kinase Yes Yes [28]
Notch1 Receptor/transcription cofactor precursor Yes Yes [29]
Notch4/Int3 Receptor/transcription cofactor precursor Yes No [30]
Wnt/int1 Morphogen Yes No [2]
Wnt3 Morphogen Yes No [31]
Wnt10b Morphogen Yes Yes [32]
MMTV, mouse mammary tumour virus.Page 3 of 4
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the brain tumours discussed above because of tissue tropism
of the retroviruses. Transposon-mediated IM may be more
widely applicable and is highly efficient, as has been shown in
Caenorhabtidis elegans and  Drosophila  [16,17]. DNA
transposons are discrete DNA elements that are able to
translocate within the cellular genome by excision and
reinsertion mediated by a transposase, which can be
encoded by the transposable DNA element or can be located
elsewhere in the genome. No active DNA transposons have
been identified in mammalian genomes. However, recently no
fewer than three papers described artificial transposable
elements designed for IM in the mouse. Dupuy [18] and Collier
[19] and their coworkers used an adapted Sleeping Beauty
(SB) transposon that was originally resurrected from
evolutionary inactive elements in fish DNA, whereas Ding and
colleagues [20] adapted PiggyBac (PB) derived from a DNA
transposable element in a cabbage moth. Both are binary
systems (i.e. the transposase and transposon are independently
transmitted and can be maintained in different animals that can
be interbred to mobilize the transposon). PB was shown to
efficiently integrate and transpose randomly not only in cell lines
but also in the mouse germ line. This transposon may thus be
particularly useful for germ line IM. However, the low number of
transpositions per generation or cell division may limit the use of
PB for cancer gene discovery in its present form.
Dupuy [18] and Collier [19] and their coworkers have adapted
the SB system more specifically for IM in somatic cells by
providing the transposon with viral promoter and enhancer
elements for gene activation, and splice donor, acceptor and
polyadenylation sequences for induction of intragenic
insertional mutations by gene trapping. SB efficiently mobilizes
in somatic cells and reinserts in or close to genes, thereby
modifying gene expression and/or interrupting coding
sequences by similar mechanisms as employed by
retroviruses. However, DNA transposons hop through the
genome by a cut and paste mechanism and proliferate very
slowly, which is inhibitory for efficient somatic mutagenesis.
Dupuy [18] and Collier [19] and their coworkers solved this
problem with SB to some extent by introducing large
concatamers containing up to 300 copies of the transposon
into the mouse genome. A shortcoming of the SB system
used by Collier and coworkers [19] is its tendency to
transpose to locations close to the excision site. This means
that even after several rounds of transposition the majority of
the transposons still tend to land on the same chromosome.
The transposon density on the originating chromosome can
be so high that the significance of the less frequently tagged
loci may be doubted. Although mobilization of the Dupuy
variant was more efficient, allowing the transposons to spread
wider and to different chromosomes, this system suffered from
a high incidence of embryonic lethality and a strong
predispostion to haematopoietic tumours. Both issues may be
resolved by the use of tissue-specific and/or inducible SB-
based mutagenesis systems, in which tissue specificity and/or
timing of transposase activity can be controlled.
Conclusion
Discovery of new genes with a causal role in cancer and
delineation of the pathways through which these genes act
form the basis for designing novel cancer treatments.
Retroviral IM has already proven to be invaluable for this
purpose and transposon-mediated IM will broaden further its
application to malignancies other than lymphomas and
mammary tumours. Because lymphoma genes tagged by
transposons only partly overlap with genes targeted by
retroviruses, both technologies may complement each other.
Exhaustive screening for IM screens will yield many genes
with such a low contribution to oncogenesis that therapeutic
targeting of these genes or gene products is ineffective. This
may be particularly true for infrequently hit genes. Moreover,
the availability of the Retrovirus Tagged Cancer Gene
Database [13] in principle allows different studies to be
combined, and it may be tempting to conclude that loci that
are sporadically hit in separate studies are common, without
consideration of statistics. However, the genomic window in
which the insertions must be present for a statistically
meaningful CIS will become very small as the number of
analyzed insertions increases [5]. The size of such windows
may even be overestimated, because both proviruses and
transposons tend to land preferentially in transcriptionally
active regions of the genome [21]. Furthermore, the affected
gene may not always simply be the adjacent gene. This means
that candidate cancer genes identified from IM screens should
ultimately be validated in an oncogenicity study.
Another point to consider is that cancer genes may affect
different tissues when they are mutated in mice and in
humans; therefore, conclusions of experiments obtained with
murine cancer genes should be carefully assessed before
applying them to human cancer. Searching the available
microarray expression data for over-expression of the studied
mouse gene in human cancer may already provide a quick
indication of the relevance of this gene for human cancer.
Extrapolating from the number of genes found by IM in
lymphomas, we may expect a large number of novel
candidate oncogenes to be discovered by IM in other tissues.
In mammary carcinogenesis the novel genes will come from
MMTV-mediated IM, and the list will probably be completed
by transposon tagging. In other tumours the full benefit of
transposon-mediated IM will be obtained. The next challenge
will be to prove the true contributions of all these genes to
oncogenesis, to find the pathways in which they act, and to
exploit this knowledge for therapy.
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